Adc Therapeutics SA Stock

$2.71

0.37% yesterday

NYSE, Jun 27, 10:00 pm CET

ISIN

CH0499880968

Symbol

ADCT

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Adc Therapeutics SA Stock price

$2.71

-43.23 94.10% 5Y

NYSE, Closing price Fri, Jun 27 2025

+0.01 0.37%

ISIN

CH0499880968

Symbol

ADCT

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$268.8m

Enterprise Value

$514.7m

Net debt

$245.9m

Cash

$194.7m

Shares outstanding

99.2m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

3.54 | 3.43

EV/Sales

6.79 | 6.57

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-62.94%

Return on Equity

77.89%

ROCE

-58.44%

ROIC

-237.83%

Debt/Equity

-1.85

Financials (TTM | estimate)

Revenue

$75.8m | $78.4m

EBITDA

$-121.8m | $-169.3m

EBIT

$-125.5m

Net Income

$-149.8m | $-135.4m

Free Cash Flow

$-136.7m

Growth (TTM | estimate)

Revenue

-37.54% | 10.65%

EBITDA

55.83% | -32.93%

EBIT

54.62%

Net Income

60.73% | 14.25%

Free Cash Flow

9.33%

Margin (TTM | estimate)

Gross

92.75%

EBITDA

-160.60% | -216.02%

EBIT

-165.54%

Net

-197.64% | -172.69%

Free Cash Flow

-180.27%

EPS

$-1.39

FCF per Share

$-1.38

Short interest

5.81%

Employees

264.00

Rev per Employee

$270.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Adc Therapeutics SA Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Adc Therapeutics SA forecast:

11x Buy

92%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Adc Therapeutics SA forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Adc Therapeutics SA

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	76 76	38% 38% 100%
- Direct Costs	5.50 5.50	8% 8% 7%
Gross Profit	70 70	39% 39% 93%
- Selling and Administrative Expenses	83 83	53% 53% 109%
- Research and Development Expense	113 113	47% 47% 149%
EBITDA	-122 -122	56% 56% -161%
- Depreciation and Amortization	3.75 3.75	326% 326% 5%
EBIT (Operating Income) EBIT	-126 -126	55% 55% -166%
Net Profit	-150 -150	61% 61% -198%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Adc Therapeutics SA Stock News

Neutral

PRNewsWire

●

12 days ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69% CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment ZYNLONTA was generally well tolerated and safety was consistent with known profile LAUSANNE, Switzerland , June 16, 2025 /PRNewswire/ -...

Neutral

PRNewsWire

●

16 days ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

LAUSANNE, Switzerland , June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ("PIPE") finan...

Neutral

PRNewsWire

●

16 days ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable saf...

More Adc Therapeutics SA News

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Head office	Switzerland
CEO	Ameet Mallik
Employees	264
Founded	2011
Website	adctherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now